Chargement en cours...
Everolimus and Malignancy after Solid Organ Transplantation: A Clinical Update
Malignancy after solid organ transplantation remains a major cause of posttransplant mortality. The mammalian target of rapamycin (mTOR) inhibitor class of immunosuppressants exerts various antioncogenic effects, and the mTOR inhibitor everolimus is licensed for the treatment of several solid cancer...
Enregistré dans:
| Publié dans: | J Transplant |
|---|---|
| Auteurs principaux: | , , |
| Format: | Artigo |
| Langue: | Inglês |
| Publié: |
Hindawi Publishing Corporation
2016
|
| Sujets: | |
| Accès en ligne: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5078653/ https://ncbi.nlm.nih.gov/pubmed/27807479 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1155/2016/4369574 |
| Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|